Welcome to our dedicated page for Procter & Gamble SEC filings (Ticker: PG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Procter & Gamble Company (PG) files a wide range of documents with the U.S. Securities and Exchange Commission, providing detailed insight into its operations, capital structure, governance, and shareholder policies. As a New York Stock Exchange‑listed issuer with common stock and multiple series of notes registered under Section 12(b) of the Exchange Act, P&G uses SEC filings to report material events, financing activities, executive and director matters, and shareholder meeting results.
Recent Form 8‑K filings illustrate the types of information investors can find. Regulation FD 8‑Ks document quarterly dividend declarations on common stock and ESOP convertible preferred stock, along with the company’s long record of consecutive dividend payments and increases. Other 8‑Ks report underwritten public offerings of U.S. dollar, euro, and pound sterling notes with various maturities, including floating rate notes and fixed‑rate notes issued under a shelf registration statement on Form S‑3, with related legal opinions filed as exhibits.
Additional 8‑Ks address governance topics such as the approval of The Procter & Gamble 2025 Stock and Incentive Compensation Plan, voting results from the Annual Meeting of Shareholders, and retirement announcements for senior executives. Earnings‑related 8‑Ks furnish quarterly results, slides used on earnings calls, and notices of webcasts. Together with the company’s proxy statement on Schedule 14A, these filings give a structured view of P&G’s executive compensation framework, board composition, and strategic priorities.
On this page, Stock Titan provides real‑time access to Procter & Gamble’s SEC filings as they appear on EDGAR, along with AI‑powered summaries to help explain the significance of each document. Users can quickly review annual and quarterly reports, current reports on Form 8‑K, and exhibits related to new debt offerings or compensation plans, as well as monitor items such as dividend announcements and shareholder vote outcomes without reading every page of the underlying filings.
Procter & Gamble Company (PG) filing a Form 144 notifies the proposed sale of 13,677 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE with an aggregate market value of $2,118,635.69. The shares were acquired on 08/18/2025 as a Performance Stock Program Award from The Procter & Gamble Company and payment/vesting is recorded on 08/18/2025. The approximate date of sale listed is 08/19/2025. The filer indicates there have been no sales in the past three months and attests to possessing no undisclosed material adverse information.
Procter & Gamble Company (PG) Form 144 notice discloses a proposed sale of 12,353 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $1,913,541.47. The shares are reported as acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company, with an approximate sale date of 08/19/2025. The filing lists 2,342,371,488 shares outstanding for the class. No securities of the issuer were reported sold by the person in the prior three months. The filer represents there is no undisclosed material adverse information and notes the criminal penalties for misstatement.
The filing is a Form 144 notice reporting a proposed sale of 10,094 shares of Procter & Gamble Company common stock through Morgan Stanley Smith Barney LLC on the New York Stock Exchange, with an aggregate market value of $1,563,611.07, and an approximate sale date of 08/19/2025. The shares were acquired on 08/18/2025 under a Performance Stock Program Award from Procter & Gamble and 21,372 shares are shown as the amount acquired on that date for the award. The filer represents they are not aware of any undisclosed material adverse information about the issuer.
Form 144 filed for Procter & Gamble Company (PG). The filer notified intent to sell 15,328 shares of common stock through Morgan Stanley Smith Barney LLC on 08/19/2025, with an aggregate market value of $2,374,383.84. The shares were acquired on 08/18/2025 as a Performance Stock Program Award from The Procter & Gamble Company, totaling 30,815 shares received and showing 2,342,371,488 shares outstanding. The filer reported no sales in the past three months and included the standard representation that they are not aware of undisclosed material adverse information. The notice indicates the transaction will be executed on the NYSE.
Form 144 notice for Procter & Gamble (PG) shows a proposed sale of 376 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an aggregate market value of $58,244.28 and approximately 2,342,371,488 shares outstanding. The securities were acquired on 08/18/2025 as a Performance Stock Program Award from The Procter & Gamble Company and payment was recorded on 08/18/2025. No securities of the issuer were reported sold by the filer in the past three months. The filer affirms they are not aware of undisclosed material adverse information about the issuer.
Procter & Gamble Company (PG) Form 144 notice: The filer notified intent to sell 10,686 shares of Procter & Gamble common stock through Morgan Stanley Smith Barney on 08/19/2025 on the NYSE. The filing lists an aggregate market value of $1,655,314.83 and reports 2,342,371,488 shares outstanding. The shares to be sold were acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company; the acquisition quantity is reported as 22,496 shares with payment on 08/18/2025. The filer attests there is no undisclosed material adverse information and includes the standard signature and criminal-penalty notice applicable to Form 144.
Procter & Gamble (PG) filing a Rule 144 notice shows a proposed sale of company common stock through Morgan Stanley Smith Barney LLC on 08/19/2025. The notice lists two lots: 929 shares with an aggregate market value of $143,906.75 and 12,963 shares with an aggregate market value of $2,008,033.52. The total outstanding shares reported for the issuer are 2,342,371,488, making the proposed sale a vanishingly small fraction of the company’s float.
The securities were acquired on 08/18/2025 as Performance Stock Program awards from The Procter & Gamble Company and payment/consideration is listed as NA. The filer certifies there are no known undisclosed material adverse facts and reports no securities sold by the person in the past three months.
Procter & Gamble (PG) Form 144 notice: The filer reports a proposed sale of 47,232 shares of Procter & Gamble common stock, with an aggregate market value of $7,316,472.96, to be executed through Morgan Stanley Smith Barney LLC on the NYSE on 08/19/2025. The securities were acquired the prior day, 08/18/2025, as a Performance Stock Program Award from The Procter & Gamble Company, totaling 89,360 shares awarded and paid on 08/18/2025.
The filing states there were 2,342,371,488 shares outstanding at the time of the notice and reports no securities sold by the person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Procter & Gamble Form 144 notice reports a proposed sale of 714 shares of common stock, with an aggregate market value of $110,602.17, to be sold on the NYSE on or about 08/19/2025. The shares were acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company and were paid for on 08/18/2025. The filing lists total shares outstanding of 2,342,371,488, indicating the sale is immaterial relative to the companys total float. The filer certifies they are unaware of any undisclosed material adverse information and provides standard Rule 144 representations regarding trading plans and compliance.
Form 144 notice for Procter & Gamble Company (PG). The filer notifies intent to sell 11,198 shares of Common Stock through Morgan Stanley Smith Barney LLC on the NYSE with an approximate sale date of 08/19/2025. The aggregate market value of the proposed sale is reported as $1,734,626.19 and the issuer's shares outstanding are shown as 2,342,371,488. The securities were acquired on 08/18/2025 under a Performance Stock Program Award from The Procter & Gamble Company; the filer lists acquiring 18,834 shares and indicates payment on 08/18/2025. No sales in the past three months are reported. The notice includes the standard representation about lack of undisclosed material adverse information.